Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Non-malignant573 active trials4 approved drugs14 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Clinical trials
2,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01088347 | Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 9 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03476798 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium(Clovis-001) | completed | Phase 2 | 49 | University of OklahomaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06226350 | A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | completed | Phase 2 | 29 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02481414 | A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions | completed | Phase 2 | 81 | University of ArkansasOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04590599 | A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | completed | Phase 2 | 205 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | completed | Phase 2 | 52 | Nykode Therapeutics ASAINDUSTRY | 6 | Dec 15, 2023 | clinicaltrials |
| NCT04246489 | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | completed | Phase 2 | 146 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Oct 23, 2023 | clinicaltrials |
| NCT04542356 | Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | completed | Phase 2 | 60 | Chongqing University Cancer HospitalOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT02740777 | Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females | completed | Phase 2 | 900 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03816553 | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | completed | Phase 2 | 25 | Gradalis, Inc.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT01399658 | Image-Guided Gynecologic Brachytherapy(AMIGO) | completed | Phase 2 | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02921269 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Nov 8, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02866006 | Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer | completed | Phase 1 / Phase 2 | 32 | Cellid Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01590017 | Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer | completed | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 27, 2022 | clinicaltrials |
| NCT02529930 | An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | completed | Phase 1 / Phase 2 | 34 | Nykode Therapeutics ASAINDUSTRY | 1 | Jul 13, 2022 | clinicaltrials |
| NCT04436133 | Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | completed | Phase 2 | 480 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04188847 | First-line Chemotherapy for Recurrent Cervical Cancer | completed | Phase 2 | 37 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04188860 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | completed | Phase 2 | 34 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02728258 | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 11 | NRG OncologyOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05149248 | Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study(CONDESA) | completed | Phase 2 / Phase 3 | 6,000 | Instituto Nacional de Salud Publica, MexicoOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03192059 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer(PRIMMO) | completed | Phase 2 | 43 | University Hospital, GhentOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02394652 | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03935204 | Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | completed | Phase 2 | 627 | Xiamen UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | completed | Phase 1 / Phase 2 | 10 | Inovio PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02093598 | POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus(POEM) | completed | Phase 2 | 10 | MedSIROTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 2 | Feb 17, 2020 | clinicaltrials |
| NCT03540407 | Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | completed | Phase 2 | 66 | Catalysis SLINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02849340 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00319748 | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Apr 19, 2024source: clinicaltrials